表紙
市場調査レポート

髄膜炎菌血症 - パイプライン製品の分析

Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014

発行 Global Markets Direct 商品コード 245996
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
髄膜炎菌血症 - パイプライン製品の分析 Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014
出版日: 2014年03月31日 ページ情報: 英文 58 Pages
概要

髄膜炎菌血症は髄膜炎菌によって引き起こされる細菌性の感染症で、症状は発熱、頭痛、皮疹、吐き気などです。治療には抗菌薬および昇圧剤の投与、呼吸補助などが行われます。

当レポートでは、髄膜炎菌血症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

髄膜炎菌血症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • GlaxoSmithKline plc
  • Biological E. Limited
  • Novartis AG
  • Panacea Biotec Limited
  • Wellstat Vaccines, LLC
  • Beijing Minhai Biotechnology Co., Ltd
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Sanofi Pasteur SA

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • Meninge ACYW Conjugate
  • Nimenrix
  • Meningococcal ACW135 Vaccine (Plain)
  • Meningococcal ACYW135 Vaccine (Plain)
  • Meningococcal ACYW135X Vaccine (Plain)
  • MenABCWY Conjugate Vaccine
  • Meningitis Vaccine
  • Meningococcus CY Polysaccharide Conjugate Vaccine
  • Meningococcal B Vaccine
  • ABC Meningococcal Vaccine
  • Meningococcus B Vaccine
  • Meningococcal Vaccine
  • Meningococcal Conjugate Vaccine

パイプライン製品の最新動向

休止中のプロジェクト

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC4743IDB

Global Markets Direct's, 'Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014', provides an overview of the Meningococcemia (Meningococcal Infections)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Meningococcemia (Meningococcal Infections)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Meningococcemia (Meningococcal Infections) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Meningococcemia (Meningococcal Infections) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Meningococcemia (Meningococcal Infections) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Meningococcemia (Meningococcal Infections)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Meningococcemia (Meningococcal Infections) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Meningococcemia (Meningococcal Infections) Overview
  • Therapeutics Development
    • Pipeline Products for Meningococcemia (Meningococcal Infections) - Overview
    • Pipeline Products for Meningococcemia (Meningococcal Infections) - Comparative Analysis
  • Meningococcemia (Meningococcal Infections) - Therapeutics under Development by Companies
  • Meningococcemia (Meningococcal Infections) - Therapeutics under Investigation by Universities/Institutes
  • Meningococcemia (Meningococcal Infections) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Meningococcemia (Meningococcal Infections) - Products under Development by Companies
  • Meningococcemia (Meningococcal Infections) - Products under Investigation by Universities/Institutes
  • Meningococcemia (Meningococcal Infections) - Companies Involved in Therapeutics Development
    • GlaxoSmithKline plc
    • Biological E. Limited
    • Novartis AG
    • Panacea Biotec Limited
    • Wellstat Vaccines, LLC
    • Beijing Minhai Biotechnology Co., Ltd
    • Chongqing Zhifei Biological Products Co., Ltd.
    • Sanofi Pasteur SA
  • Meningococcemia (Meningococcal Infections) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Meninge ACYW Conjugate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nimenrix - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal ACW135 Vaccine (Plain) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal ACYW135 Vaccine (Plain) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal ACYW135X Vaccine (Plain) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MenABCWY Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningitis Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcus CY Polysaccharide Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal B Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ABC Meningococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcus B Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Meningococcal Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Meningococcemia (Meningococcal Infections) - Recent Pipeline Updates
  • Meningococcemia (Meningococcal Infections) - Dormant Projects
  • Meningococcemia (Meningococcal Infections) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 24, 2014: Novartis provides second US university with Bexsero to help protect students and staff against potentially deadly meningitis B disease
      • Dec 09, 2013: Health Canada Approves Bexsero, the First Vaccine Available to Prevent Meningococcal Serogroup B
      • Jan 14, 2013: Novartis's Bexsero Shows Potential To Help Provide Broad Protection To Infants Against MenB In Phase III Clinical Trial
      • Dec 03, 2012: Sanofi Pasteur Canada Receives Health Canada Approval Of Menactra Meningococcal Conjugate Vaccine Indication For Infants
      • Nov 08, 2012: Sanofi Pasteur Announces Publication Of Pivotal Safety And Immunogenicity Data Of Menactra Vaccine For Infants And Toddlers
      • Feb 13, 2012: FDA Requests Additional Data On Novartis's Quadrivalent Meningococcal Conjugate Vaccine, Menveo For Expanded Use In Infants And Toddlers
      • Jun 16, 2011: FDA Accepts Novartis's Menveo sBLA For Review
      • May 12, 2011: Novartis Provides Update On Phase III Study Of Menveo Vaccine To Treat Meningococcal Disease
      • Apr 22, 2011: Sanofi Pasteur Announces FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication for Infants
      • Jan 31, 2011: FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo, for use in children from 2 years of age
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Meningococcemia (Meningococcal Infections), H1 2014
  • Number of Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by GlaxoSmithKline plc, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Biological E. Limited, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Novartis AG, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Panacea Biotec Limited, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Wellstat Vaccines, LLC, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014
  • Meningococcemia (Meningococcal Infections) - Pipeline by Sanofi Pasteur SA, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Meningococcemia (Meningococcal Infections) Therapeutics - Recent Pipeline Updates, H1 2014
  • Meningococcemia (Meningococcal Infections) - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Meningococcemia (Meningococcal Infections), H1 2014
  • Number of Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top